SI2297359T1 - Profili genskega izraĹľanja za napovedovanje izida raka dojke - Google Patents

Profili genskega izraĹľanja za napovedovanje izida raka dojke

Info

Publication number
SI2297359T1
SI2297359T1 SI200930853T SI200930853T SI2297359T1 SI 2297359 T1 SI2297359 T1 SI 2297359T1 SI 200930853 T SI200930853 T SI 200930853T SI 200930853 T SI200930853 T SI 200930853T SI 2297359 T1 SI2297359 T1 SI 2297359T1
Authority
SI
Slovenia
Prior art keywords
gene expression
breast cancer
expression profiles
cancer outcomes
predict breast
Prior art date
Application number
SI200930853T
Other languages
English (en)
Inventor
Charles M. Perou
Joel S. Parker
James Stephen Marron
Andrew Nobel
Philip S. Bernard
Matthew Ellis
Elaine Mardis
Torsten O. Nielsen
Maggie Cheang
Original Assignee
The University Of North Carolina At Chapel Hill
University Of Utah Research Foundation
Washington University
British Columbia Cancer Agency Branch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of North Carolina At Chapel Hill, University Of Utah Research Foundation, Washington University, British Columbia Cancer Agency Branch filed Critical The University Of North Carolina At Chapel Hill
Publication of SI2297359T1 publication Critical patent/SI2297359T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SI200930853T 2008-05-30 2009-06-01 Profili genskega izraĹľanja za napovedovanje izida raka dojke SI2297359T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5750808P 2008-05-30 2008-05-30
EP09770678.2A EP2297359B1 (en) 2008-05-30 2009-06-01 Gene expression profiles to predict breast cancer outcomes
PCT/US2009/045820 WO2009158143A1 (en) 2008-05-30 2009-06-01 Gene expression profiles to predict breast cancer outcomes

Publications (1)

Publication Number Publication Date
SI2297359T1 true SI2297359T1 (sl) 2014-05-30

Family

ID=41202871

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200930853T SI2297359T1 (sl) 2008-05-30 2009-06-01 Profili genskega izraĹľanja za napovedovanje izida raka dojke

Country Status (13)

Country Link
US (7) US9631239B2 (sl)
EP (2) EP2297359B1 (sl)
JP (3) JP5740302B2 (sl)
AU (1) AU2009262894B2 (sl)
CA (1) CA2725760C (sl)
CY (1) CY1114993T1 (sl)
DK (1) DK2297359T3 (sl)
ES (2) ES2650610T3 (sl)
HR (1) HRP20140140T1 (sl)
PL (1) PL2297359T3 (sl)
PT (1) PT2297359E (sl)
SI (1) SI2297359T1 (sl)
WO (1) WO2009158143A1 (sl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5740302B2 (ja) * 2008-05-30 2015-06-24 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 乳癌の予後を予測するための遺伝子発現プロフィール
ES2546089T3 (es) * 2009-01-23 2015-09-18 Bergen Teknologioverforing As Métodos para determinar un pronóstico de supervivencia para una paciente con cáncer de mama
US9771618B2 (en) 2009-08-19 2017-09-26 Bioarray Genetics, Inc. Methods for treating breast cancer
WO2011061568A1 (en) * 2009-11-22 2011-05-26 Azure Vault Ltd. Automatic chemical assay classification
BR112012024718A2 (pt) * 2010-03-31 2017-01-10 Sividon Diagnostics Gmbh método para a predição da recorrência de câncer da mama sob tratamento endócrino
AU2012211964A1 (en) * 2011-02-04 2013-08-22 Bioarray Genetics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
US9066963B2 (en) * 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
EP2737081B1 (en) 2011-07-28 2016-09-28 Sividon Diagnostics GmbH Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer
CN103997894B (zh) 2011-07-29 2016-08-24 麦迪韦逊***治疗股份有限公司 乳癌的治疗
CN104024851A (zh) * 2011-11-28 2014-09-03 加拿大国家研究委员会 针对癌症的紫杉醇反应标志物
CA2857505A1 (en) * 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
CN104704128A (zh) * 2012-05-22 2015-06-10 纳米线科技公司 预测乳腺癌结果的nano46基因和方法
US9002438B2 (en) 2012-05-30 2015-04-07 Lucerno Dynamics System for the detection of gamma radiation from a radioactive analyte
US9939533B2 (en) 2012-05-30 2018-04-10 Lucerno Dynamics, Llc System and method for the detection of gamma radiation from a radioactive analyte
US9890430B2 (en) 2012-06-12 2018-02-13 Washington University Copy number aberration driven endocrine response gene signature
WO2014005010A2 (en) 2012-06-29 2014-01-03 Nanostring Technologies, Inc. Methods of treating breast cancer with gemcitabine therapy
CN102719547B (zh) * 2012-07-02 2013-10-09 厦门大学 检测her2基因表达水平的实时荧光定量pcr试剂盒
US20150299797A1 (en) * 2012-08-24 2015-10-22 University Of Utah Research Foundation Compositions and methods relating to blood-based biomarkers of breast cancer
WO2014071218A2 (en) * 2012-11-02 2014-05-08 University Of Utah Research Foundation Biomarkers for breast cancer and methods of using same
WO2014075067A1 (en) * 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
EP2951317B1 (en) 2013-02-01 2017-10-11 Sividon Diagnostics GmbH Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
JP2016519935A (ja) * 2013-05-13 2016-07-11 ナノストリング テクノロジーズ，インコーポレイティド 結節陽性の初期乳癌における再発リスクを予測する方法
EP2959021B1 (en) * 2013-08-19 2018-08-08 BioNTech Diagnostics GmbH Methods and kits for the molecular subtyping of tumors
HUE040066T2 (hu) 2013-08-19 2019-02-28 Biontech Diagnostics Gmbh Eljárások és felszerelések tumorok molekuláris szubtipizálásához
US10665347B2 (en) 2013-08-20 2020-05-26 Ohio State Innovation Foundation Methods for predicting prognosis
US20150072021A1 (en) 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy
KR101560880B1 (ko) 2013-10-15 2015-10-19 이화여자대학교 산학협력단 유방암의 예후 판단을 위한 정보를 제공하는 방법
WO2015084968A1 (en) 2013-12-03 2015-06-11 University Of Massachusetts System and methods for predicting probable relationships between items
EP3108013B1 (en) * 2014-02-18 2019-09-18 Dignity Health Lkb1 related diagnostics and treatments of cancer
US11434535B2 (en) * 2014-05-17 2022-09-06 The Regents Of The University Of California Centromere/kinetochore protein genes for cancer diagnosis, prognosis and treatment selection
EP4029952A1 (en) 2014-11-21 2022-07-20 Nanostring Technologies, Inc Enzyme- and amplification-free sequencing
JP7144142B2 (ja) 2014-11-24 2022-09-29 ナノストリング テクノロジーズ，インコーポレイティド 遺伝子精製および画像化のための方法および装置
JP2018500895A (ja) * 2014-12-09 2018-01-18 キングス・カレッジ・ロンドン タキサン療法による乳癌治療
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
US20180038866A1 (en) * 2015-02-27 2018-02-08 Industry-Academic Cooperation Foundation, Yonsei University Apparatus and method for determining prognosis of breast cancer and whether to use chemotherapy
US11174518B2 (en) * 2015-10-05 2021-11-16 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
CN109072481B (zh) * 2015-12-07 2022-03-18 安大略省癌症研究所 早期乳腺癌内分泌治疗后剩余风险的基因特征
CA3022377A1 (en) * 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
SG11201809913PA (en) 2016-05-16 2018-12-28 Nanostring Technologies Inc Methods for detecting target nucleic acids in a sample
US10934590B2 (en) 2016-05-24 2021-03-02 Wisconsin Alumni Research Foundation Biomarkers for breast cancer and methods of use thereof
WO2018039490A1 (en) 2016-08-24 2018-03-01 Genomedx Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018074865A2 (ko) * 2016-10-21 2018-04-26 서울대학교병원 유방암 예후 예측용 조성물 및 방법
CA3043489A1 (en) 2016-11-21 2018-05-24 Nanostring Technologies, Inc. Chemical compositions and methods of using same
ES2674327B2 (es) * 2016-11-28 2018-12-17 Geicam - Grupo Español De Investigacion En Cancer De Mama CES: un índice quimioendocrino basado en PAM50 para el cáncer de mama con receptores hormonales positivos con un riesgo intermedio de recidiva
KR101874716B1 (ko) * 2016-12-14 2018-07-04 연세대학교 산학협력단 유방암 분자아형 분류방법 및 이를 이용한 유방암 분자아형 분류 디바이스
WO2018160925A1 (en) * 2017-03-02 2018-09-07 President And Fellows Of Harvard College Methods and systems for predicting treatment responses in subjects
AU2018230784A1 (en) * 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
SG11201911820RA (en) * 2017-06-16 2020-01-30 Nantomics Llc Prognostic indicators of poor outcomes in praegnant metastatic breast cancer cohort
CA3075265A1 (en) 2017-09-08 2019-03-14 Myriad Genetics, Inc. Method of using biomarkers and clinical variables for predicting chemotherapy benefit
IT201700109459A1 (it) * 2017-09-29 2019-03-29 Univ Degli Studi Di Perugia Metodo per effettuare prognosi del cancro della mammella, kit ed uso di questi
US20200357484A1 (en) * 2017-11-08 2020-11-12 Koninklijke Philips N.V. Method for simultaneous multivariate feature selection, feature generation, and sample clustering
WO2019165366A1 (en) * 2018-02-23 2019-08-29 Beth Israel Deaconess Medical Center Drug efficacy evaluations
CA3099909A1 (en) 2018-05-14 2019-11-21 Nanostring Technologies, Inc. Chemical compositions and methods of using same
KR101966589B1 (ko) * 2018-06-20 2019-04-05 연세대학교 산학협력단 유방암 분자아형 분류방법 및 이를 이용한 유방암 분자아형 분류 디바이스
EP3874062A4 (en) * 2018-11-04 2022-08-24 PFS Genomics, Inc. METHODS AND GENOMIC CLASSIFIERS FOR PRODICTING BREAST CANCER AND PREDICTING THE BENEFITS OF ADJUVANT RADIATION THERAPY
CN109801680B (zh) * 2018-12-03 2023-02-28 广州中医药大学(广州中医药研究院) 基于tcga数据库的肿瘤转移复发预测方法及***
WO2020178399A1 (en) 2019-03-05 2020-09-10 Norwegian University Of Science And Technology (Ntnu) Breast cancer signature genes
CN109913551A (zh) * 2019-03-26 2019-06-21 深圳大学 乳腺癌分型的核酸组合物、乳腺癌分型试剂盒及其使用方法
CN111508555A (zh) * 2020-04-15 2020-08-07 淮南师范学院 一组用于度量生物分子集的网络拓扑学特性的方法
CN112626218A (zh) * 2021-01-07 2021-04-09 浙江科技学院 一种用于预测胰腺癌转移风险的基因表达分类器、体外诊断试剂盒
RU2762317C1 (ru) * 2021-02-24 2021-12-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в основном опухолевом узле у больных раком молочной железы
AU2022245322A1 (en) * 2021-03-25 2023-10-05 Oncxerna Therapeutics, Inc. Targeted therapies in cancer
WO2023250397A1 (en) * 2022-06-21 2023-12-28 Bioventures, Llc Methods for the molecular subtyping of tumors from archival tissue
CN115144599B (zh) * 2022-09-05 2023-01-06 西湖大学 蛋白组合在制备对儿童甲状腺癌进行预后分层的试剂盒中的用途及其试剂盒、***

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US20040235039A1 (en) 1990-03-20 2004-11-25 Regents Of The University Of California Chromosome-specific staining to detect genetic rearrangements
WO1993006121A1 (en) 1991-09-18 1993-04-01 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US6025126A (en) 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
EP0624059A4 (en) 1991-11-22 1994-12-21 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis.
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
EP1027456B1 (en) 1997-10-31 2005-03-16 Affymetrix, Inc. (a Delaware Corporation) Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
CA2527285A1 (en) 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP2947160B1 (en) 2004-04-09 2017-07-12 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2006010150A2 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
JP2006141210A (ja) 2004-11-16 2006-06-08 Hitachi Ltd キメラ遺伝子の検出方法
WO2007061876A2 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
AU2006330834B2 (en) 2005-12-23 2013-09-12 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
ES2374788T3 (es) 2005-12-23 2012-02-22 Nanostring Technologies, Inc. Nanoinformadores y métodos para su producción y uso.
US7892740B2 (en) 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
US20090239223A1 (en) 2006-07-13 2009-09-24 Siemens Healthcare Diagnostics Inc. Prediction of Breast Cancer Response to Taxane-Based Chemotherapy
EP2155899A2 (en) 2007-04-10 2010-02-24 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
JP5740302B2 (ja) 2008-05-30 2015-06-24 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 乳癌の予後を予測するための遺伝子発現プロフィール
JP5836803B2 (ja) 2008-08-14 2015-12-24 ナノストリング テクノロジーズ， インコーポレイテッド 安定したナノレポーター
GB2467691A (en) 2008-09-05 2010-08-11 Aueon Inc Methods for stratifying and annotating cancer drug treatment options
WO2010039275A1 (en) 2008-10-03 2010-04-08 Oligonix, Inc. Method, array and system for detecting intergenic fusions
WO2010061269A2 (en) 2008-11-02 2010-06-03 Optimata Ltd. Improving cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf)
ES2546410T3 (es) 2009-08-06 2015-09-23 John Wayne Cancer Institute Diagnosis de cáncer de mama, y otros tipos de cáncer, de tipo basal primario y metastásico
AU2010326154A1 (en) 2009-12-01 2012-06-28 Precision Therapeutics, Inc. Multi drug response markers for breast cancer cells
EP2558599A4 (en) 2010-04-14 2013-11-13 Nuvera Biosciences Inc METHODS OF ASSESSING ANTICANCER THERAPY RESPONSE
US9066963B2 (en) 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
WO2012135340A2 (en) 2011-03-28 2012-10-04 Nanostring Technologies, Inc. Compositions and methods for diagnosing cancer
CA2857505A1 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
CN104704128A (zh) 2012-05-22 2015-06-10 纳米线科技公司 预测乳腺癌结果的nano46基因和方法
WO2014005010A2 (en) 2012-06-29 2014-01-03 Nanostring Technologies, Inc. Methods of treating breast cancer with gemcitabine therapy
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US20150072021A1 (en) 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy

Also Published As

Publication number Publication date
US20160168645A1 (en) 2016-06-16
US20160153051A1 (en) 2016-06-02
JP2011524162A (ja) 2011-09-01
PL2297359T4 (pl) 2014-07-31
WO2009158143A1 (en) 2009-12-30
US20230250484A1 (en) 2023-08-10
JP5740302B2 (ja) 2015-06-24
JP2017127330A (ja) 2017-07-27
AU2009262894A1 (en) 2009-12-30
EP2664679A1 (en) 2013-11-20
ES2457534T3 (es) 2014-04-28
EP2664679B1 (en) 2017-11-08
JP6140202B2 (ja) 2017-05-31
US9631239B2 (en) 2017-04-25
DK2297359T3 (en) 2014-02-24
CA2725760C (en) 2019-07-02
ES2650610T3 (es) 2018-01-19
US20200040407A1 (en) 2020-02-06
US20110145176A1 (en) 2011-06-16
US20190264290A1 (en) 2019-08-29
HRP20140140T1 (en) 2014-05-23
EP2297359B1 (en) 2013-11-13
PT2297359E (pt) 2014-03-19
JP2015119716A (ja) 2015-07-02
CY1114993T1 (el) 2016-12-14
EP2297359A1 (en) 2011-03-23
CA2725760A1 (en) 2009-12-30
AU2009262894B2 (en) 2014-01-30
PL2297359T3 (pl) 2014-07-31
US20220213563A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
HRP20140140T1 (en) Gene expression profiles to predict breast cancer outcomes
IL276487B (en) Methods for predicting clinical outcome of cancer
IL212905A0 (en) Individualized cancer dignosis
EP2382331A4 (en) KREBSBIOMARKER
HK1175476A1 (en) Cancer treatment
ZA201201107B (en) Cancer metastasis inhibitor
EP2310006A4 (en) TREATMENT OF CANCER
IL210504A0 (en) Genetic variants for breast cancer risk assessment
PL2460403T3 (pl) Mysi model stłuszczeniowego zapalenia wątroby-raka wątroby
AP3679A (en) Continuous mining
GB0904957D0 (en) Tumour gene profile
GB201117107D0 (en) Methods for predicting cancer response to EGFR inhibitors
GB0804496D0 (en) Treating cancer
HK1192150A1 (zh) 新型癌抗原
ZA201201981B (en) Cancer cell apoptosis
HK1160123A1 (zh) 苯基咪唑化合物
EP2467140A4 (en) METHOD FOR CANCER TREATMENT
IL214476A0 (en) Method for predicting breast and ovarian cancer risk
IL213919A0 (en) Methods to treat cancer
EP2321641A4 (en) GENE METHYLATION IN THE DIAGNOSIS OF CANCER
GB0800934D0 (en) Time zone calculator
GB201002366D0 (en) Cancer prognosis
GB0902065D0 (en) Calculator
GB0921102D0 (en) Cancer Therapy
GB0913603D0 (en) Cancer therapy